IBI-Ag Overview
IBI-Ag is focused on the discovery and development of new types of biological solutions that utilize environmentally friendly technology to control insects. The company utilizes breakthrough technology to produce efficient, selective, and safe biological insect-control solutions. IBI-Ags technology is highly cost-effective due to its fermentation suitability, enabling farmers to produce agricultural produce at low cost.
Cumulative Funding Raised Over Time ($)
$500KApr 2017
$6.6MFeb 2025
$6.7MJun 2018
$7.7MJun 2018
$7.7MJun 2021
Latest News
growth-positive
The company’s single-domain antibody technology aims to redefine sustainable agriculture.
IBI Ag, a company specializing in bio-insecticides with a lower ecological footprint, has secured $6.1 million in the first part of its Series A funding round. The investment was led by Corteva, Inc., with participation from The Trendlines Group, Iron Nation, Consensus Business Group, and a grant from the Israel Innovation Authority. IBI Ag is developing technology using single-domain antibodies to create effective crop protection solutions that minimize environmental impact. The funding will accelerate the development of this technology, initially targeting high-value crops with plans to expand into row crops.
Investment
growth-positive
/PRNewswire/ -- IBI Ag, a pioneering crop protection company developing a wide array of bio-insecticides with a lower ecological footprint, today announced it...
IBI Ag, a company focused on developing sustainable bioinsecticides, has successfully closed the first tranche of its Series A funding round, raising $6.1 million. The investment was led by Corteva through its Corteva Catalyst platform, with participation from The Trendlines Group, Iron Nation, Consensus Business Group, and a grant from the Israel Innovation Authority. IBI Ags technology uses single domain antibodies to create effective crop protection solutions with minimal ecological impact. The funding will accelerate the development of this technology, which targets a broad spectrum of insects and aims to provide environmentally friendly alternatives to chemical pesticides.
Investment
growth-positive
Exclusive: IBI Ag clinches $6.1m round led by Corteva to scale up 'cost-effective' bioinsecticides
IBI Ag, an Israel-based bioinsecticide company, has raised $6.1 million in the first tranche of its Series A funding round. The round was led by Corteva through its investment and partnership platform, Corteva Catalyst, and included participation from the Trendlines Group, Iron Nation, Consensus Business Group, and the Israel Innovation Authority. IBI Ag specializes in developing cost-effective nanobodies for agricultural use, which are smaller and more efficient than traditional antibodies. The company is currently conducting field trials and plans to start the regulatory process in the US by the end of the year. The funding will be used to scale up production and regulatory efforts, with plans to expand into Latin America and Europe.
InvestmentPartnersProduct Stage
growth-positive
IBI Ag, a Nes Tziona, Israel-based crop protection company, raised $6.1M in funding
IBI Ag, an Israel-based crop protection company, has raised $6.1 million in funding. The investment round was led by Corteva and included participation from The Trendlines Group, Iron Nation, Consensus Business Group, and a grant from the Israel Innovation Authority. The funds will be used to strengthen the companys position in the global agricultural sector by developing innovative crop protection solutions. IBI Ags technology uses single domain antibodies to create effective and environmentally friendly crop protection products, targeting a wide range of insects while minimizing impact on non-target organisms.
Investment
growth-positive
החברה שרוצה להדביר את חומרי ההדברה
Israeli ag-tech company IBIAg is developing a new generation of bio-insecticides that are safe for the environment and can be used immediately before consumption. The companys products are based on a tiny antigen that, when modified using biotechnology, can kill pests. IBIAg, which has received around $6 million in investment to date, is currently in the lab testing phase and expects to have its first product ready within two years.
Investment
| Sector | Agriculture & Food Technologies |
Funding
| Total funding | $7.74M |
| Last funding | $6.1M |
| Stage | A |
| Rounds | 5 |
| Investors | 7 |
Team Members
4
Employees: 11-50
Web & Social Links
| Website | www.ibi-ag.com/ |
Locations
Ness Ziona, Israel
Photos & Videos
1 item(s)
IBI-Ag Business
Business models
B2B
Product stage
R&D
Employees
11-50
Sector
Climate TechFood & Land UseSustainable FarmingAgriculture & Food TechnologiesAg TechFarm Equipment & TreatmentTarget Customer
Agriculture & FoodCropsCore Technology
BiologicalsTags (6)
climate-techagriculturefarmersagtechpesticidesplant-protectionGeographic Markets
GlobalIBI-Ag Financials
$7.74M
Total funding
Undisclosed
Capital raised
$6.1M
Last funding
A
Funding stage
5
Total rounds
7
Investors
Cumulative Funding Raised Over Time ($)
$500KApr 2017
$6.6MFeb 2025
$6.7MJun 2018
$7.7MJun 2018
$7.7MJun 2021
Private Equity Funding
A Round
Feb 2025
$6.1M
Iron Nation, Corteva, The Trendlines Group, Consensus Business Group (CBG)
Undisclosed Round
Jun 2021
Undisclosed
Bayer Trendlines Ag Innovation Fund (Lead)
,
Agriline, The Trendlines Group
Seed
Jun 2018
$140K
Bayer Trendlines Ag Innovation Fund
Seed
Jun 2018
$1M
The Trendlines Group, Israel Innovation Authority
Seed
Apr 2017
$500K
Bayer Trendlines Ag Innovation Fund
IBI-Ag Lifecycle
Cumulative Funding Raised Over Time
$500KApr 2017
$6.6MFeb 2025
$6.7MJun 2018
$7.7MJun 2018
$7.7MJun 2021
All Events
A Round
Feb 2025
$6.1M
Iron Nation, Corteva, The Trendlines Group, Consensus Business Group (CBG)
Undisclosed Round
Jun 2021
Undisclosed
Bayer Trendlines Ag Innovation Fund (Lead)
,
Agriline, The Trendlines Group
Seed
Jun 2018
$140K
Bayer Trendlines Ag Innovation Fund
Seed
Jun 2018
$1M
The Trendlines Group, Israel Innovation Authority
Seed
Apr 2017
$500K
Bayer Trendlines Ag Innovation Fund
IBI-Ag News
7 articles
growth-positive
The company’s single-domain antibody technology aims to redefine sustainable agriculture.
IBI Ag, a company specializing in bio-insecticides with a lower ecological footprint, has secured $6.1 million in the first part of its Series A funding round. The investment was led by Corteva, Inc., with participation from The Trendlines Group, Iron Nation, Consensus Business Group, and a grant from the Israel Innovation Authority. IBI Ag is developing technology using single-domain antibodies to create effective crop protection solutions that minimize environmental impact. The funding will accelerate the development of this technology, initially targeting high-value crops with plans to expand into row crops.
Investment
growth-positive
/PRNewswire/ -- IBI Ag, a pioneering crop protection company developing a wide array of bio-insecticides with a lower ecological footprint, today announced it...
IBI Ag, a company focused on developing sustainable bioinsecticides, has successfully closed the first tranche of its Series A funding round, raising $6.1 million. The investment was led by Corteva through its Corteva Catalyst platform, with participation from The Trendlines Group, Iron Nation, Consensus Business Group, and a grant from the Israel Innovation Authority. IBI Ags technology uses single domain antibodies to create effective crop protection solutions with minimal ecological impact. The funding will accelerate the development of this technology, which targets a broad spectrum of insects and aims to provide environmentally friendly alternatives to chemical pesticides.
Investment
growth-positive
Exclusive: IBI Ag clinches $6.1m round led by Corteva to scale up 'cost-effective' bioinsecticides
IBI Ag, an Israel-based bioinsecticide company, has raised $6.1 million in the first tranche of its Series A funding round. The round was led by Corteva through its investment and partnership platform, Corteva Catalyst, and included participation from the Trendlines Group, Iron Nation, Consensus Business Group, and the Israel Innovation Authority. IBI Ag specializes in developing cost-effective nanobodies for agricultural use, which are smaller and more efficient than traditional antibodies. The company is currently conducting field trials and plans to start the regulatory process in the US by the end of the year. The funding will be used to scale up production and regulatory efforts, with plans to expand into Latin America and Europe.
InvestmentPartnersProduct Stage
growth-positive
IBI Ag, a Nes Tziona, Israel-based crop protection company, raised $6.1M in funding
IBI Ag, an Israel-based crop protection company, has raised $6.1 million in funding. The investment round was led by Corteva and included participation from The Trendlines Group, Iron Nation, Consensus Business Group, and a grant from the Israel Innovation Authority. The funds will be used to strengthen the companys position in the global agricultural sector by developing innovative crop protection solutions. IBI Ags technology uses single domain antibodies to create effective and environmentally friendly crop protection products, targeting a wide range of insects while minimizing impact on non-target organisms.
Investment
growth-positive
החברה שרוצה להדביר את חומרי ההדברה
Israeli ag-tech company IBIAg is developing a new generation of bio-insecticides that are safe for the environment and can be used immediately before consumption. The companys products are based on a tiny antigen that, when modified using biotechnology, can kill pests. IBIAg, which has received around $6 million in investment to date, is currently in the lab testing phase and expects to have its first product ready within two years.
Investment
growth-positive
IBI-Ag Completes Funding Round for its New Class of Bioinsecticides
IBI-Ag, a biotechnology company, has announced an investment round to optimize its first product and expand its product portfolio spectrum. The round includes investments from the Bayer-Trendlines Ag Innovation Fund, Agriline, and The Trendlines Group. IBI-Ag is developing natural, single domain antibody insecticides to increase crop production without harm to farmers, consumers, and the environment. The company aims to provide novel and effective nature-driven solutions to the insect pest problem in agriculture. The investment round is seen as a vote of confidence in IBI-Ags progress and its commitment to environmental sustainability.
Investment
Bayer Trendlines Ag Innovation Fund makes first investment - The Trendlines Group
IBI-Ag Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 19 |
| Team members | 4 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 13 classification IDs that could be used for matching.
IBI-Ag Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 90/100 |
| Missing | markets, not claimed |
| BI Verification | Fredrik Liljedahl |
| Registrar ID | 515646578 |
| Crunchbase | ibi-ag |
| Creator | Fredrik Liljedahl |
| Creator email | fredrik.liljedahl@sncentral.org |
| Last updater | Ortal Wein |
| Updater email | ortalw@sncentral.org |
| Last update | 2023-05-15T00:00:00.000Z |
| Created | 2017-07-09T00:00:00.000Z |